Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
Dahat A. Hussein(Kurdistan Regional Government), Guy Makin(Royal Manchester Children's Hospital), Caroline Dive(University of Manchester), Sarah V. Holt(Pharma Nord (United Kingdom)), Tetyana Klymenko(Queen Mary University of London), Karen E. Brookes(Cancer Research UK Manchester Institute), Timothy H. Ward(Cancer Research UK Manchester Institute), Jennifer Adamski(Cancer Research UK Manchester Institute), EJ Estlin(Royal Manchester Children's Hospital), Alison Hogg(Cancer Research UK Manchester Institute)
Cited by 15
Related Papers
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642
Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression
|Journal of Cell Science|2004|344
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
|The Lancet Oncology|2015|282
Vasculogenic mimicry in small cell lung cancer
|Nature Communications|2016|243
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse
|Nature Medicine|2019|230